| Yazarlar |
Bülent Özlek
Türkiye |
|
Eda Özlek
Türkiye |
|
Oğuzhan Çelik
Türkiye |
|
Cem Çil
Türkiye |
|
Volkan Doğan
Muğla Sıtkı Koçman Üniversitesi, Türkiye |
|
Mehmet Tekinalp
Türkiye |
|
Hicaz Zencirkıran Ağuş
Türkiye |
|
Serkan Kahraman
İstanbul Rumeli Üniversitesi, Türkiye |
|
Altuğ Ösken
Türkiye |
Prof. Dr. İbrahim RENCÜZOĞULLARI
Kafkas Üniversitesi, Türkiye |
|
Veysel Ozan Tanık
Türkiye |
|
Lütfü Bekar
Hitit Üniversitesi, Türkiye |
|
Mustafa Ozan Çakır
Zonguldak Bülent Ecevit Üniversitesi, Türkiye |
|
Bedri Caner Kaya
Sağlık Bilimleri Üniversitesi, Türkiye |
|
Hakan Tibilli
Türkiye |
|
Yunus Çelik
Türkiye |
|
Özcan Başaran
Türkiye |
|
Kadir Uğur Mert
Eskişehir Osmangazi Üniversitesi, Türkiye |
|
Samet Sevinç
Türkiye |
|
Erkan Demirci
Türkiye |
|
Engin Dondurmacı
Türkiye |
|
Murat Biteker
Muğla Sıtkı Koçman Üniversitesi, Türkiye |
| Özet |
| Objective: Although almost half of chronic heart failure (HF) patients have mid-range (HFmrEF) and preserved left-ventricular ejection fraction(HFpEF), no studies have been carried out with these patients in our country. This study aims to determine the demographic characteristics andcurrent status of the clinical background of HFmrEF and HFpEF patients in a multicenter trial.Methods: A comPrehensive, ObservationaL registry of heart faiLure with mid-range and preserved ejectiON fraction (APOLLON) trial will bean observational, multicenter, and noninterventional study conducted in Turkey. The study population will include 1065 patients from 12 sites inTurkey. All data will be collected at one point in time and the current clinical practice will be evaluated (ClinicalTrials.gov number NCT03026114).Results: We will enroll all consecutive patients admitted to the cardiology clinics who were at least 18 years of age and had New York HeartAssociation class II, III, or IV HF, elevated brain natriuretic peptide levels within the last 30 days, and an left ventricular ejection fraction (LVEF)of at least 40%. Patients fulfilling the exclusion criteria will not be included in the study. Patients will be stratified into two categories accordingto LVEF: mid-range EF (HFmrEF, LVEF 40%-49%) and preserved EF (HFpEF, LVEF ≥50%). Regional quota sampling will be performed to ensure thatthe sample was representative of the Turkish population. Demographic, lifestyle, medical, and therapeutic data will be collected by this specificsurvey.Conclusion: The APOLLON trial will be the largest and most comprehensive study in Turkey evaluating HF patients with a LVEF ≥40% and will alsobe the first study to specifically analyze the recently designated HFmrEF category. |
| Anahtar Kelimeler |
| Makale Türü | Özgün Makale |
| Makale Alt Türü | SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale |
| Dergi Adı | The Anatolian Journal of Cardiology |
| Dergi ISSN | 2149-2263 |
| Dergi Tarandığı Indeksler | SCI-Expanded |
| Makale Dili | İngilizce |
| Basım Tarihi | 01-2018 |
| Cilt No | 19 |
| Sayfalar | 311 / 318 |
| Doi Numarası | 10.14744/AnatolJCardiol.2018.95595 |
| Makale Linki | https://www.journalagent.com/anatoljcardiol/pdfs/AJC-95595-ORIGINAL_INVESTIGATION-OZLEK.pdf |
| Atıf Sayıları | |
| TRDizin | 3 |
